Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2030-2039

  Tepper, J E ^a   O'Connell, M J ^a   Petroni, G R ^a   Hollis, D ^a   Cooke, E ^a   Benson III, A B ^a   Cummings, B ^a   Gunderson, L L ^a   Macdonald, J S ^a   Martenson, J A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CANCER;

EID: 0030994521     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2030     Document Type: Article

References (25)

1. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465-1472, 1985
2. O'Connell MJ, Martenson J, Wieand H, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
3. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10:549-557, 1992
4. Poon M, O'Connell M, Moertel C, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1417, 1989
5. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
6. Erlichman C, Fine S, Wong A, et al: Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
7. Windle R, Bell P, Shaw D: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 74:569-572, 1987
8. Laurie J, Moertel C, Fleming T, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447-1456, 1989
9. Moertel C, Fleming T, MacDonald J, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
10. Agresti A: Categorical Data Analysis. New York, NY, Wiley, 1990
11. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135:185-206, 1972
13. Cox D: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
14. Therneau T, Grambach P, Fleming T: Martingale based residuals for survival models. Biometrika 77:147-160, 1990
15. Schoenfeld D: Partial residuals for the proportional hazards regression models. Biometrika 69:239-241, 1982
16. Krook J, Moertel C, Gunderson L, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
17. Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 80:21-29, 1988
18. Petrelli N, Douglas H, Herrera L, et al: Modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
19. Haller D, Catalano P, Macdonald J, et al: Fluorouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089. Proc Am Soc Clin Oncol 15:211, 1996 (abstr)
20. Wolmark N, Rockett H, Mamounas E, et al: Relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV) and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with dukes' B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 15:205, 1996 (abstr)
21. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
22. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995
23. O'Connell M, Mailliard J, Kahn M, et al: A controlled trial of 5-fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
24. Coia L, Hoffman J, Scher R, et al: Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 30:161-167, 1994
25. O'Dwyer P, Ryan L, Valone F, et al: Phase III trial of biochemical modulation of 5-fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 15:207, 1996 (abstr)